4108-88-7

Usage

Uses

Used in Pharmaceutical Industry:
1-Pyrrolidinesulfonamide(7CI,8CI,9CI) is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs and treatments.
Used in Agrochemical Industry:
In the agrochemical sector, 1-Pyrrolidinesulfonamide(7CI,8CI,9CI) serves as an intermediate in the production of agrochemicals, playing a role in the creation of compounds that can enhance crop protection and yield.
Used in Organic Compounds Synthesis:
1-Pyrrolidinesulfonamide(7CI,8CI,9CI) is utilized as a building block in the synthesis of various organic compounds, highlighting its versatility in chemical reactions and its potential to form a wide range of products.
Used in Surfactant Production:
As an intermediate in the production of surfactants, 1-Pyrrolidinesulfonamide(7CI,8CI,9CI) contributes to the creation of compounds that are essential in industries such as detergents, cleaning products, and personal care products due to their ability to reduce surface tension and stabilize emulsions.
Used in Pigment and Dye Manufacturing:
1-Pyrrolidinesulfonamide(7CI,8CI,9CI) is employed in the manufacturing of pigments and dyes, where it aids in the development of colorants used in various applications, including textiles, plastics, and printing inks.
Used in Medical Research:
In the field of medical research, 1-Pyrrolidinesulfonamide(7CI,8CI,9CI) has been studied for its potential applications in the development of new drugs and treatments, showcasing its importance in advancing healthcare solutions.

InChI:InChI=1S/C4H10N2O2S/c5-9(7,8)6-3-1-2-4-6/h1-4H2,(H2,5,7,8)

Upstream product

• 874124-81-9 [N-(tert-butoxycarbonyl)]-pyrrolidine-1-sulfonic acid amide 
• 123-75-1 pyrrolidine 
• 108555-00-6 4-nitrophenyl sulfamate 

Downstream Products

• 1211973-51-1 2-fluoro-N-(pyrrolidin-1-ylsulfonyl)benzamide 
• 1211973-64-6 4-chloro-N-(pyrrolidin-1-ylsulfonyl)benzamide 
• 1211973-47-5 N-(pyrrolidin-1-ylsulfonyl)benzamide 
• 1211973-63-5 4-methoxy-N-(pyrrolidin-1-ylsulfonyl)benzamide 
• 1211973-60-2 3-chloro-N-(pyrrolidin-1-ylsulfonyl)benzamide 
• 1253286-62-2 C₁₂H₁₃F₃N₂O₃S 
• 1211973-58-8 3-methoxy-N-(pyrrolidin-1-ylsulfonyl)benzamide 
• 1211973-50-0 2-chloro-N-(pyrrolidin-1-ylsulfonyl)benzamide 
• 1253286-65-5 4-tert-butyl-N-(pyrrolidin-1-ylsulfonyl)benzamide 
• 1211973-49-7 2-methoxy-N-(pyrrolidin-1-ylsulfonyl)benzamide 
• 1211973-48-6 2-methyl-N-(pyrrolidin-1-ylsulfonyl)benzamide 
• 1253286-64-4 N₁,N₁-dimethyl-N₄-(pyrrolidin-1-ylsulfonyl)terephthalamide 
• 1211973-62-4 4-cyano-N-(pyrrolidin-1-ylsulfonyl)benzamide 
• 1422251-74-8 C₂₉H₃₆N₄O₆S 

Relevant academic research and scientific papers

7-(2-anilinopyrimidin-4-yl)-1-benzazepin-2-ones designed by a “cut and glue” strategy are dual aurora a/vegf-r kinase inhibitors

Although overexpression and hyperactivity of protein kinases are causative for a wide range of human cancers, protein kinase inhibitors currently approved as cancer drugs address only a limited number of these enzymes. To identify new chemotypes addressing alternative protein kinases, the basic structure of a known PLK1/VEGF-R2 inhibitor class was formally dissected and reassembled. The resulting 7-(2-anilinopyrimidin-4-yl)-1-benzazepin-2-ones were synthesized and proved to be dual inhibitors of Aurora A kinase and VEGF receptor kinases. Crystal structures of two representatives of the new chemotype in complex with Aurora A showed the ligand orientation in the ATP binding pocket and provided the basis for rational structural modifications. Congeners with attached sulfamide substituents retained Aurora A inhibitory activity. In vitro screening of two members of the new kinase inhibitor family against the cancer cell line panel of the National Cancer Institute (NCI) showed antiproliferative activity in the single-digit micromolar concentration range in the majority of the cell lines.

NEW BRAF INHIBITORS AS PARADOX BREAKERS

The invention provides a novel compound having the general formula (I) (I) wherein R1-R3 and X are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) cardiovascular disease; (ii) metabolic disorders; (iii) diseases, disorders, and conditions associated with vascular pathology; and (iv) organ failure; (v) diseases, disorders, and conditions associated with infections (e.g., microbial infections); and (vi) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include pulmonary hypertension (e.g., PAH); heart failure; type II diabetes; renal failure; sepsis; and systemic hypertension.

VITAMIN E FORMULATIONS OF SULFAMIDE NS3 INHIBITORS

The invention relates to new formulations of compounds having activity against HCV-associated disorders, new combinations, new methods of treatment and their use in therapy.

Organic compounds and their uses

The present application describes organic compounds of Formula (II) that are useful for the treatment, prevention and/or amelioration of human diseases.

1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE

A compound represented by formula (1) (in the formula: ring-D represents a three- to eight-membered hydrocarbon ring; Ra represents an optionally substituted amino C1-6 alkyl group or the like; Rb1 and Rb2 each independently represent a hydrogen atom, a halogen atom, or the like; Rc represents an optionally substituted C6-10 aryl group or the like; Rd represents a hydrogen atom or the like; and ring-Q represents a (hetero)aryl group or the like which may be substituted with a carboxyl group or the like) or a pharmaceutically acceptable salt thereof exhibits an excellent FXIa inhibitory activity, and is useful as a therapeutic agent against thrombosis or the like.

SUBSTITUTED PYRAZOLO[1,5-A] PYRIDINE AS TROPOMYOSIN RECEPTOR KINASE (TRK) INHIBITORS

The present application relates to a series of substituted pyrazolo[1,5-a]pyridine compounds, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.

SUBSTITUTED PYRAZOLO[1,5-A] PYRIDINE AS TROPOMYOSIN RECEPTOR KINASE (TRK) INHIBITORS

The present application relates to a series of substituted pyrazolo[1,5-a]pyridine compounds, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors., method of making and pharmaceutical compositions comprising such compounds.

SALTS AND POLYMORPHS OF SULFAMIDE NS3 INHIBITORS

The invention provides new salts and polymorphs of (5R,8S)-7-[(2S)-2- {[(2S)-2-cyclohexyl-2-({[(2S)-1-isopropylpiperidin-2-yl] carbonyl}amino)acetyl]amino}-3,3-dimethylbutanoyl]-N-{(1R,2R)-2-ethyl-1-[(pyrrolidin-1-ylsulfonyl)carbamoyl]cyclopropyl}-10,10-dimethyl-7-azadispiro[3.0.4.1]decane-8-carboxamide (referred to herein as Compound X), pharmaceutical compositions containing them and processes for their manufacture and use in therapy

INHIBITORS OF HCV REPLICATION

Indole compounds of Formula I are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. Different forms and compositions comprising the compounds are also described as well as methods of